A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Diseases and Conditions Researched

Colon; Liver; Rectum

What is the purpose of this trial?

The objective of this study is to evaluate and compare the efficacy and safety of regorafenib vs. placebo in subjects with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Bayer Healthcare Pharmaceuticals, Inc.
Last Updated:
Study HIC#: 1402013496